Regulus Therapeutics (United States)
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2024. Read More.
Open Access Percentage
55%
Total
Publications
168
Total Open
Publications
93
Total
Citations
21K
Open Access
Percentage
55%
Total
Publications
168
Total Open
Publications
93
Total
Citations
21K
Breakdown
Publisher Open
9%
Both
30%
Other Platform Open
17%
Closed
44%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 29%
19
Hybrid 26%
17
No Guarantees 45%
29
Other Platform Open
Domain 88%
69
Institution 21%
16
Public 19%
15
Other Internet 15%
12
Preprint 6%
5
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 69 |
Europe PMC | Domain | 51 |
DOI | Other Internet | 36 |
Semantic Scholar | Public | 10 |
Figshare | Public | 8 |
California Institute of Technology - CaltechAUTHORS | Institution | 5 |
bioRxiv | Preprint | 5 |
California Digital Library - eScholarship | Other Internet | 4 |
University of California - eScholarship University of California | Institution | 2 |
University College London - UCL Discovery | Institution | 2 |